| Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20). | |
| | |
MedLine Citation:
|
PMID: 20923486 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Patients with Type 2 diabetes mellitus (T2DM) are often treated with multiple glucose-lowering and cardiovascular agents. The concomitant use of nitrates, renin-angiotensin system (RAS) blockers, or insulin has been linked to a potential increase in myocardial ischemic risk with rosiglitazone. The PROactive database provides an opportunity to investigate the effects of these medications on the potential macrovascular benefits reported with pioglitazone. METHODS: The PROactive study was a randomized double-blind prospective trial that evaluated mortality and cardiovascular morbidity in 5238 patients with T2DM and macrovascular disease. Patients received pioglitazone or placebo in addition to their baseline glucose-lowering and cardiovascular medications. The effect of pioglitazone on composite endpoints was evaluated, including all-cause death, myocardial infarction (MI), and stroke, as well as safety events of edema and serious heart failure, in subgroups using nitrates, RAS blockers, or insulin at baseline. RESULTS: The risk of all-cause death, MI, and stroke for pioglitazone versus placebo was similar regardless of the baseline use of nitrates, RAS blockers, or insulin, with hazard ratios ranging from 0.81 to 0.87. Similar results were obtained for the other composite endpoints analyzed. There were no significant interactions between baseline medication subgroups and treatment. The increased risk of edema and serious heart failure was consistent across the baseline medication subgroups. CONCLUSIONS: This post hoc analysis did not reveal an increased risk of macrovascular events with pioglitazone in patients receiving nitrates, RAS blockers, or insulin. Rather, all patients realized the same trend towards benefit with pioglitazone, and adverse events of edema and heart failure were predictable. |
| | |
Authors:
|
Erland Erdmann; Robert Spanheimer; Bernard Charbonnel; |
Related Documents
:
|
16439846 - Babies born small for gestational age: insulin sensitivity and growth hormone treatment. 15606696 - The association of smoking and subclinical atherosclerosis in type 2 diabetes: modifica... 18484806 - Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. 758126 - Diabetes and cardiovascular risk factors: the framingham study. 6439586 - Sorbitol dehydrogenase deficiency in several pig tissues: potential implications for st... 2576006 - Muscarinic stimulation and antagonism and glucoregulation in nondiabetic and obese hype... |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Journal of diabetes Volume: 2 ISSN: 1753-0407 ISO Abbreviation: J Diabetes Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-10-06 Completed Date: 2011-02-02 Revised Date: 2011-03-28 |
Medline Journal Info:
|
Nlm Unique ID: 101504326 Medline TA: J Diabetes Country: Australia |
Other Details:
|
Languages: eng Pagination: 212-20 Citation Subset: IM |
Copyright Information:
|
© 2010 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Blackwell Publishing Asia Pty Ltd. |
Affiliation:
|
Medizinische Klinik III der Universität zu Köln, Köln, Germany. erland.erdmann@uni-koeln.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Age of Onset Aged Angiotensin-Converting Enzyme Inhibitors / adverse effects, therapeutic use Diabetes Mellitus, Type 2 / complications, drug therapy*, mortality Diabetic Angiopathies / drug therapy, epidemiology*, mortality Edema / drug therapy, epidemiology Female Heart Failure / drug therapy, epidemiology Humans Hypoglycemic Agents / adverse effects, therapeutic use* Insulin / adverse effects, therapeutic use Male Middle Aged Multicenter Studies as Topic Myocardial Ischemia / chemically induced*, epidemiology Nitrates / adverse effects, therapeutic use Thiazolidinediones / adverse effects, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 0/Hypoglycemic Agents; 0/Nitrates; 0/Thiazolidinediones; 11061-68-0/Insulin; 111025-46-8/pioglitazone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Benefits of self-monitoring blood glucose in the management of new-onset Type 2 diabetes mellitus: t...
Next Document: Distinctions between islet neogenesis and ?-cell replication: implications for reversal of Type 1 an...